Abstract
Raloxifene is used to prevent or treat postmenopausal osteoporosis at a dose of 60 mg daily. Compared with calcium plus vitamin D, raloxifene seems more effective in reducing vertebral fractures in postmenopausal women. Compared with calcium plus vitamin D, raloxifene is not more effective in reducing nonvertebral fractures in postmenopausal women. Raloxifene may be associated with venous thromboembolic events and fatal strokes in postmenopausal women, although the association with fatal strokes was only seen in one study of women at high risk of cardiac events. No excess risk of coronary events is seen with raloxifene. Raloxifene may be less effective than certain bisphosphonates in preventing nonvertebral fractures, although no head-to-head comparisons are available.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
